Loading clinical trials...

Evaluation of an Investigational Blood Glucose Monitoring System | Clinical Trials | Clareo Health

COMPLETEDNA

Evaluation of an Investigational Blood Glucose Monitoring System

Performance of the Ninja 3 Blood Glucose Monitoring System

NCT01859494•Ascensia Diabetes Care

Summary

The purpose of this study was to determine if untrained subjects who have diabetes can operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose results.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Males and females, 18 years of age and older
•2. People with type 1 or type 2 diabetes
•3. Able to speak, read, and understand English
•4. Willing to complete all study procedures

Exclusion Criteria

•1. Hemophilia or any other bleeding disorder
•2. Pregnancy
•3. Physical, visual, or neurological impairments that would make the person unable to perform testing with the BGM
•4. Previously participated in a BG monitor study using the Ninja 3 BGMS
•5. Working for a medical laboratory, hospital, or other clinical setting that involves training on and clinical use of blood glucose monitors
•6. Working for a competitive medical device company, or having an immediate family member who works for such a company
•7. A condition which, in the opinion of the investigator or designee, would put the person or study conduct at risk.
•The enrollment criteria for the study population:
•1. At least 60% of subjects will be younger than age 65
•2. At least 20% of subjects will have type 1 diabetes
+1 more criteria

Locations (2)

AMCR Institute

Escondido, California, United States

Rainier Clinical Research Center

Renton, Washington, United States

Key Dates

Start Date

April 1, 2013

Primary Completion Date

May 1, 2013

Completion Date

May 1, 2013

Last Updated

February 10, 2017

Enrollment

219

ACTUAL participants

Conditions

Diabetes

Interventions

NINJA 3 Investigational Blood Glucose Monitoring System

DEVICE

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

RECRUITINGNA

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of an Investigational Blood Glucose Monitoring System

Inclusion Criteria

Exclusion Criteria

Genetic Studies of Insulin and Diabetes

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes